argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
argenx (NASDAQ:ARGX) reported $1.13 billion in third-quarter 2025 global product net sales and total operating income of $1.15 billion for the quarter.
Q3 operating profit was $346 million and profit for the period was $344 million. Cash and current financial assets totaled $4.3 billion as of September 30, 2025. Management reaffirmed combined R&D and SG&A guidance of ~$2.5 billion and outlined near-term development milestones including an sBLA filing for seronegative gMG by year-end 2025 and topline ADAPT-OCULUS results in 1H26. The company expects five registrational readouts in 2026 and expanded a FUJIFILM manufacturing partnership with a new North Carolina site.
argenx (NASDAQ:ARGX) ha riportato 1,13 miliardi di dollari di vendite nette globali di prodotti nel terzo trimestre 2025 e un reddito operativo totale di 1,15 miliardi di dollari per il trimestre.
L’utile operativo del Q3 è stato di 360 milioni di dollari e l’utile per il periodo è stato di 344 milioni di dollari. La liquidità e gli strumenti finanziari correnti ammontano a 4,3 miliardi di dollari al 30 settembre 2025. Il management ha confermato le guidance combinate per R&D e SG&A di circa 2,5 miliardi di dollari e ha delineato traguardi di sviluppo a breve termine, tra cui la sottomissione di un sBLA per gMG seronegativo entro la fine del 2025 e i risultati topline ADAPT-OCULUS nella prima metà del 2026. L’azienda prevede cinque risultati registrativi nel 2026 e ha ampliato una partnership di produzione con FUJIFILM con un nuovo sito in North Carolina.
argenx (NASDAQ:ARGX) informó 1,13 mil millones de dólares en ventas netas globales de productos en el tercer trimestre de 2025 y un ingreso operativo total de 1,15 mil millones de dólares para el trimestre.
La utilidad operativa del 3T fue de 346 millones de dólares y la utilidad del periodo fue de 344 millones de dólares. La caja y los activos financieros corrientes totalizaron 4,3 mil millones de dólares al 30 de septiembre de 2025. La dirección reafirmó la guía combinada de I+D y SG&A de aproximadamente 2,5 mil millones de dólares y delineó hitos de desarrollo a corto plazo, incluida la presentación de un sBLA para gMG seronegativo antes de fin de 2025 y los resultados topline ADAPT-OCULUS en 1S26. La compañía espera cinco resultados registrables en 2026 y expandió una asociación de fabricación con FUJIFILM con un nuevo sitio en Carolina del Norte.
argenx (NASDAQ:ARGX) 는 2025년 3분기 글로벌 제품 순매출 11억 3천만 달러 및 분기 총영업이익 11억 5천만 달러를 보고했습니다.
3분기 영업이익은 3억 46백만 달러이고 기간 이익은 3억 44백만 달러였습니다. 현금 및 당좌 금융자산은 2025년 9월 30일 기준 43억 달러였습니다. 경영진은 R&D 및 SG&A의 합산 가이던스를 대략 25억 달러로 재확인하고, 2025년 말까지 seronegative gMG에 대한 sBLA 제출 및 1H26의 ADAPT-OCULUS topline 결과와 같은 단기 개발 마일스톤을 제시했습니다. 또한 2026년에는 다섯 건의 등록 읽기가 예상되며 FUJIFILM 제조 파트너십을 확대하고 노스캐롤로나에 신규 사이트를 확보했습니다.
argenx (NASDAQ:ARGX) a enregistré 1,13 milliard de dollars de ventes nettes mondiales de produits au troisième trimestre 2025 et un résultat opérationnel total de 1,15 milliard de dollars pour le trimestre.
Le bénéfice opérationnel du T3 était de 346 millions de dollars et le résultat net de la période était de 344 millions de dollars. La trésorerie et les actifs financiers courants s'élevaient à 4,3 milliards de dollars au 30 septembre 2025. La direction a réaffirmé l'orientation combinée R&D et SG&A d'environ 2,5 milliards de dollars et a delineé des jalons de développement à court terme, notamment le dépôt d'un sBLA pour gMG séro-négatif d'ici la fin de 2025 et les résultats topline ADAPT-OCULUS au cours du 1er semestre 2026. L'entreprise prévoit cinq lectures registrational en 2026 et a élargi un partenariat de fabrication avec FUJIFILM avec un nouveau site en Caroline du Nord.
argenx (NASDAQ:ARGX) meldete 1,13 Milliarden Dollar an globalen Nettosverkäufen von Produkten im dritten Quartal 2025 und ein Gesamtbetriebsergebnis von 1,15 Milliarden Dollar für das Quartal.
Das operative Ergebnis im Q3 betrug 346 Millionen Dollar und der Periodengewinn betrug 344 Millionen Dollar. Barbestände und liquide Mittel belaufen sich per 30. September 2025 auf 4,3 Milliarden Dollar. Das Management bestätigte die Gesamtrichtung für F&E und SG&A von ca. 2,5 Milliarden Dollar und skizzierte kurzfristige Entwicklungsmeilensteine, einschließlich der Einreichung eines sBLA für seronegatives gMG bis Ende 2025 und topline ADAPT-OCULUS-Ergebnisse im 1H26. Das Unternehmen erwartet fünf registrierungsrelevante Ergebnisse im Jahr 2026 und hat eine Erweiterung der Fertigungspartnerschaft mit FUJIFILM an einem neuen Standort in North Carolina angekündigt.
argenx (NASDAQ:ARGX) أبلغت عن 1.13 مليار دولار من المبيعات الصافية العالمية للمنتجات في الربع الثالث من 2025 وإيرادات تشغيل إجمالية قدرها 1.15 مليار دولار للربع.
كان الربح التشغيلي للربع الثالث 346 مليون دولار وربحية الفترة 344 مليون دولار. بلغت النقدية والأصول المالية الجارية 4.3 مليار دولار حتى 30 سبتمبر 2025. أكدت الإدارة توجيهات البحث والتطوير والتكاليف الإدارية والبيعية المجمّعة بما يقرب من 2.5 مليار دولار وحددت معالم تطوير قريبة بما في ذلك تقديم sBLA لـ gMG غير المصنّف seronegative بنهاية 2025 ونتائج ADAPT-OCULUS الأولية في النصف الأول من 2026. تتوقع الشركة خمسة نتائج تسجيلية في 2026 ووسعت شراكة التصنيع مع FUJIFILM بموقع جديد في ولاية كارولاينا الشمالية.
- Product net sales of $1.13B in Q3 2025
- Operating profit of $346M in Q3 2025
- Profit for period of $344M in Q3 2025
- Cash and financial assets totaling $4.3B as of Sept 30, 2025
- On track to file sBLA for seronegative gMG by year-end 2025
- Topline ADAPT-OCULUS results expected in 1H26
- R&D expense $992M for nine months (Jan–Sept 2025)
- Total operating expenses $805M in Q3 2025
- Cost of sales increased to $109M in Q3 2025 from $59M
- Stopped empasiprubart development in dermatomyositis due to enrollment
Insights
Strong commercial momentum: VYVGART delivered large revenue growth and regulatory/market expansions that materially strengthen near‑term cash generation.
Revenue and cash position drive the business model: VYVGART reported
Dependencies and risks are explicit and company‑stated: commercial growth relies on continued uptake, approvals and label expansion, including a pending sBLA filing for seronegative gMG by
Pipeline advancing broadly with several near‑term registrational readouts that could expand labeled indications if positive.
The development engine centers on efgartigimod and two other assets: ongoing registrational studies span neurology and rheumatology, with explicit topline milestones: ADAPT‑OCULUS (ocular MG) topline in
Key operational watch items and horizon: monitor the sBLA submission for seronegative gMG by
On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic
Five registrational study readouts expected in 2026 from leading immunology pipeline
Management to host conference call today at 1:30 PM CET (8:30 AM ET)
October 30, 2025 7:00 AM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update.
“argenx continues to deliver on our bold innovation agenda, driving transformational impact for patients worldwide,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “This year, we expanded our global reach with VYVGART in two blockbuster indications, advanced five registrational programs, and are on track to complete our goal of four Phase 1 molecules by year-end, reflecting our ongoing investment in innovation. VYVGART is redefining expectations for people living with gMG and CIDP, and we see continued growth potential driven by strong patient demand for better outcomes, earlier use in the treatment paradigm, and our commitment to pursuing the broadest possible labels for our medicines. We aim to leverage the successful innovation playbook of MG and CIDP as we prepare for five registrational readouts next year. Building on this momentum, our pipeline is positioned to expand into new indications and reach tens of thousands more patients—bringing us closer to our Vision 2030 goal.”
Vision 2030 Strategic Priorities
argenx is advancing its Vision 2030 strategic priorities, anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030.
Expand global VYVGART opportunity
VYVGART® (IV: efgartigimod alfa-fcab and SC: efgartigimod alfa and hyaluronidase-qvfc) is a first-and-only IgG Fc-antibody fragment that targets the neonatal Fc receptor (FcRn). It is approved in three indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and primary immune thrombocytopenia (ITP) in Japan.
- Delivered
$1.13 billion in global product net sales in the third quarter of 2025, an increase of$554 million year-over-year and$178 million quarter-over-quarter, reflecting strong fundamentals and continued confidence from patients and prescribers. - VYVGART SC prefilled syringe (PFS) for self-injection approved in Japan in September 2025; Canada decision on approval expected by end of 2025
- Supplemental Biologics License Application (sBLA) for VYVGART in three anti-acetylcholine receptor antibody negative (AChR-Ab seronegative) gMG subtypes (MuSK+, LRP4+, triple seronegative) on track for filing with U.S. Food and Drug Administration (FDA) by year-end 2025
- Pursuing label expansion through ongoing registrational studies:
- Topline results expected in first half of 2026 for ocular MG (ADAPT OCULUS)
- Topline results expected in the second half of 2026 for primary ITP (ADVANCE-NEXT)
- Expanded partnership with FUJIFILM to include new manufacturing site in North Carolina, strengthening global supply chain and supporting anticipated growth in efgartigimod and pipeline assets
Execute 10 registrational and 10 proof-of-concept studies across efgartigimod, empasiprubart and ARGX-119 to advance next wave of launches
argenx continues to demonstrate breadth and depth within its immunology pipeline, advancing multiple first-in-class product candidates with potential across high-need indications.
Efgartigimod Development
Efgartigimod is being studied in severe IgG-mediated autoimmune diseases, highlighting the broad potential of FcRn biology across several therapeutic areas including neurology, rheumatology and endocrinology.
- Registrational studies are currently ongoing in two rheumatology indications, including idiopathic inflammatory myopathies (IIM or myositis) and Sjögren’s disease
- Topline results from ALKIVIA study evaluating three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS) and dermatomyositis (DM)) expected in second half of 2026
- Topline results from UNITY study (Sjögren’s disease) expected in 2027
- Registrational study in Graves’ disease (GD) to initiate in first half of 2026, expanding development in thyroid-driven autoimmunity, including ongoing registrational studies in thyroid eye disease (TED)
- Topline results from UplighTED studies expected in second half of 2026
- Proof-of-concept studies ongoing in systemic sclerosis (SSc) and antibody mediated rejection (AMR)
- Topline Phase 2 data from lupus nephritis do not support advancing to registrational study
Empasiprubart Development
Empasiprubart, a first-in-class, monoclonal antibody that specifically binds to C2, is currently being evaluated in three indications, including multifocal motor neuropathy (MMN), CIDP and delayed graft function (DGF).
- Topline results from registrational EMPASSION study (MMN) expected in second half of 2026
- Registrational EMVIGORATE and EMNERGIZE studies ongoing (CIDP)
- Topline data from Phase 2 VARVARA study (DGF) expected around year-end 2025
- Stopped development of empasiprubart in DM due to operational challenges with enrollment of proof-of-concept EMPACIFIC study
ARGX-119 Development
ARGX-119, a first-in-class agonist antibody that targets muscle-specific kinase (MuSK), is now a registrational asset following positive proof-of-concept data in congenital myasthenic syndromes (CMS). ARGX-119 is also being evaluated in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
- CMS registrational study on track to start in 2026
- Phase 2a proof-of-concept study ongoing in ALS; topline results expected in first half of 2026
- SMA proof-of-concept study on track to start by end of 2025
Advance four new pipeline molecules and generate sustainable value through continued investment in Immunology Innovation Program
argenx continues to invest in its Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213, targeting FcRn and further solidifying argenx’s leadership in this biology; ARGX-121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which plays an important role in inflammation, and a fourth pipeline candidate, a first-in-class sweeping antibody for which the target has not yet been disclosed.
- Phase 1 study for ARGX-109 expected to complete by end of 2025; Phase 1 studies for ARGX-213 and ARGX-121 expected to complete in first half of 2026
THIRD QUARTER 2025 FINANCIAL RESULTS
argenx SE
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| (in thousands of $ except for per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||
| Product net sales | $ | 1,126,961 | $ | 572,997 | $ | 2,865,605 | $ | 1,448,915 | ||||
| Other operating income* | 24,377 | 15,881 | 60,290 | 41,904 | ||||||||
| Total operating income | $ | 1,151,338 | $ | 588,878 | $ | 2,925,895 | $ | 1,490,819 | ||||
| Cost of sales | $ | (109,426) | $ | (59,072) | $ | (300,978) | $ | (154,633) | ||||
| Research and development expenses | (355,651) | (235,940) | (992,418) | (686,195) | ||||||||
| Selling, general and administrative expenses | (336,291) | (277,698) | (937,441) | (769,392) | ||||||||
| Loss from investment in a joint venture | (3,776) | (1,981) | (8,863) | (5,294) | ||||||||
| Total operating expenses | $ | (805,144) | $ | (574,691) | $ | (2,239,700) | $ | (1,615,514) | ||||
| Operating profit/(loss) | $ | 346,194 | $ | 14,187 | $ | 686,195 | $ | (124,695) | ||||
| Financial income | $ | 42,700 | $ | 40,586 | $ | 118,217 | $ | 118,414 | ||||
| Financial expense | (993) | (676) | (3,254) | (1,760) | ||||||||
| Exchange (losses)/gains | (1,848) | 33,927 | 74,155 | 6,712 | ||||||||
| Profit/(loss) for the period before taxes | $ | 386,053 | $ | 88,024 | $ | 875,313 | $ | (1,329) | ||||
| Income tax (expense)/benefit | $ | (41,795) | $ | 3,386 | $ | (116,228) | $ | 60,208 | ||||
| Profit for the period | $ | 344,258 | $ | 91,410 | $ | 759,085 | $ | 58,879 | ||||
| Profit for the period attributable to: | ||||||||||||
| Owners of the parent | $ | 344,258 | $ | 91,410 | $ | 759,085 | $ | 58,879 | ||||
| Weighted average number of shares used for basic profit per share | 61,371,508 | 60,087,498 | 61,147,873 | 59,633,179 | ||||||||
| Basic profit per share (in $) | 5.61 | 1.52 | 12.41 | 0.99 | ||||||||
| Weighted average number of shares used for diluted profit per share | 66,441,326 | 65,636,686 | 65,944,952 | 65,024,955 | ||||||||
| Diluted profit per share (in $) | 5.18 | 1.39 | 11.51 | 0.91 | ||||||||
*Comparative figures have been presented to be consistent with the one adopted in the current period with respect to the combination of collaboration revenue and other operating income.
DETAILS OF THE FINANCIAL RESULTS
Total operating income for the three and nine months ended September 30, 2025 was
- Product net sales of VYVGART for the three and nine months ended September 30, 2025, were
$1.1 billion and$2.9 billion , respectively, compared to$0.6 billion and$1.4 billion , respectively, for the same periods in 2024. - Other operating income for the three and nine months ended September 30, 2025 was
$24 million and$60 million , respectively, compared to$16 million and$42 million , respectively, for the same periods in 2024. The other operating income in these periods primarily related to research and development tax incentives and payroll tax rebates.
Total operating expenses for the three and nine months ended September 30, 2025 were
- Cost of sales for the three and nine months ended September 30, 2025 was
$109 million and$301 million , respectively, compared to$59 million and$155 million , respectively, for the same periods in 2024. The cost of sales related to the sale of VYVGART. - Research and development expenses for the three and nine months ended September 30, 2025 were
$356 million and$992 million , respectively, compared to$236 million and$686 million , respectively, for the same periods in 2024. The research and development expenses mainly related to:
- Advancing efgartigimod across multiple severe autoimmune indications, supporting ongoing registrational and expansion studies;
- Progressing empasiprubart into multiple indications namely in MMN, DGF and CIDP;
- Executing studies for ARGX-119 in rare neuromuscular diseases, including a registrational study in CMS and proof-of-concept studies in ALS and SMA; and
- Early-stage discovery and preclinical programs to sustain long-term pipeline growth.
- Selling, general and administrative expenses for the three and nine months ended September 30, 2025 were
$336 million and$937 million , respectively, compared to$278 million and$769 million , respectively, for the same periods in 2024. The selling, general and administrative expenses mainly related to professional and marketing fees linked to global commercialization of the VYVGART franchise, and personnel expenses.
Financial income for the three and nine months ended September 30, 2025 was
Exchange losses/gains for the three and nine months ended September 30, 2025 were a
Income tax for the three and nine month periods ended September 30, 2025 and 2024 is detailed below:
| Three Months Ended | Nine Months Ended | |||||||||||
| 30 September, | 30 September, | |||||||||||
| (in millions of $) | 2025 | 2024 | 2025 | 2024 | ||||||||
| Current tax expense | $ | (52) | $ | (13) | $ | (122) | $ | (29) | ||||
| Deferred tax benefit | 10 | 17 | 6 | 89 | ||||||||
| Income tax (expense)/benefit | $ | (42) | $ | 3 | $ | (116) | $ | 60 | ||||
Profit for the three and nine month periods ended September 30, 2025 was
Cash, cash equivalents and current financial assets1 consisted of
FINANCIAL GUIDANCE
The financial guidance on the combined research and development and selling, general and administrative remains unchanged at approximately
REMAINING KEY DATES
- February 26, 2026: Full-year 2025 Financial Results and Fourth Quarter 2025 Business Update
CONFERENCE CALL DETAILS
The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay may be accessed on the Investors section of the argenx website at argenx.com/investors.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “advance,” “aim,” “ambition,” “bring,” “committed,” “continue,” “deliver,” “execute,” “expand,” “expect,” “generate,” “goal,” “improve,” “position,” “potential,” and “pursue” and include, among other things, statements argenx makes concerning its intention to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26; its advancement of five registrational programs with readouts expected in 2026 from leading immunology pipeline; its goal to complete four Phase 1 molecules by year-end; its continued growth potential driven by strong patient demand for better outcomes, earlier use in the treatment paradigm, and its commitment to pursuing the broadest possible labels for its medicines; its aim to leverage the successful innovation playbook of MG and CIDP as it prepares for five registrational readouts next year; the positioning of its pipeline to expand into new indications and reach tens of thousands more patients; its advancement of its Vision 2030 strategic priorities, anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030; the advancement of anticipated clinical development, data readouts and regulatory milestones and plans, including: (1) the PFS decision on approval expected in Canada by end of 2025, (2) the filing of the sBLA for VYVGART in three AChR-Ab seronegative gMG subtypes by year-end 2025, (3) its pursuit of label expansion through ongoing registrational studies, with topline results expected in first half of 2026 for ocular MG and second half of 2026 for primary ITP; (4) the topline results from ALKIVIA study expected in second half of 2026; (5) the topline results from UNITY study expected in 2027; (6) the registrational study in GD to initiate in first half of 2026, (7) the topline results from UplighTED studies expected in second half of 2026, (8) the topline results from registrational EMPASSION study (MMN) expected in second half of 2026, (9) the topline data from Phase 2 VARVARA study (DGF) expected around year-end 2025, (10) the expected ARGX-119 CMS registrational study start in 2026, (11) the topline results from the ARGX-119 Phase 2a proof-of-concept study expected in first half of 2026, (12) the expected ARGX-119 SMA proof-of-concept study start by end of 2025, (13) the expected completion of the Phase 1 study for ARGX-109 by end of 2025 and (14) the expected completion of the Phase 1 studies for ARGX-213 and ARGX-121 in first half of 2026; its generation of sustainable value through continued investment in Immunology Innovation Program; its commitment to improve the lives of people suffering from severe autoimmune diseases; its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines; its commercialization of the first approved neonatal Fc receptor (FcRn) blocker and evaluation of its broad potential in multiple serious autoimmune diseases; and its advancement of several earlier stage experimental medicines within its therapeutic franchises. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
Alternative Performance Measures Statement
In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets.
This value should not be viewed as a substitute for the company’s IFRS financial information and is provided as a complement to financial information provided in accordance with IFRS and should be read in conjunction with the most directly comparable IFRS financial information as set out below. Management believes this non-IFRS financial measure is useful for securities analysts, investors and other interested parties to gain a more complete understanding of the company's available financial liquidities given that the company’s current financial assets are held in term accounts with an initial maturity of more than three months but less than twelve that may be used to meet its financial obligations. Such non-IFRS financial information, as calculated herein, may not be comparable to similarly named measures used by other companies and should not be considered comparable to IFRS financial measures. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, an analysis of the company's financial results as reported under IFRS.
A reconciliation of the IFRS financial information to non-IFRS financial information is included below:
Cash, cash equivalents and current financial assets totaled
1 A non-IFRS Alternative Performance Measure (APM). Refer to the “Alternative Performance Measures Statement” below for a reconciliation to the IFRS financial information.
FAQ
How much did argenx (ARGX) report in product net sales for Q3 2025?
When will argenx file the sBLA for seronegative gMG (ARGX)?
What milestone results for ARGX should investors expect in 1H26?
What was argenx's operating profit and profit for the period in Q3 2025 (ARGX)?
How much cash and current financial assets did argenx (ARGX) hold as of Sept 30, 2025?
What major pipeline readouts does argenx (ARGX) expect in 2026?
Did argenx (ARGX) change its R&D and SG&A guidance after Q3 2025?
